A community of 30,000 US Transcriptionist serving Medical Transcription Industry
The generator was placed into an AGUS (age-us) pouch.
I think most use AIGIS, but the manufacturer’s name is AIGISRx (with the Rx being in subscript).
AIGISRx Anti-Bacterial Envelope
(Anti-Bacterial Bioresorbable Polymer-Coated Polypropylene Pacemaker Pouch Containing the Antimicrobials Rifampin and Minocycline)
Manufactured and distributed by: TYRX, Inc.
STERILE: Contents sterile unless package has been opened or damaged. Single Use Only. Do Not Resterilize.
PRODUCT DESCRIPTION
AIGISRx is a dual component (resorbable and non-resorbable), sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body.
AIGISRx is constructed of knitted filaments of polypropylene that are coated with a bioresorbable polyarylate polymer.
AIGISRx bioresorbable polymer coating contains the antimicrobial agents rifampin and minocycline in concentrations of 86 μg/cm2.
INDICATIONS FOR USE
AIGISRx is intended to securely hold a pacemaker pulse generator or defibrillator in order to create a stable environment when implanted in the body. AIGISRx contains the antimicrobial agents rifampin and minocycline which have been shown to reduce infection in an in-vivo model of bacterial challenge following surgical implantation of the generator or defibrillator. This device is only intended to be used in conjunction with pacemakers and implantable defibrillators.
ACTIONS
AIGISRx is constructed of knitted filaments of polypropylene that are coated with a bioresorbable polyarylate polymer. The purpose of the resorbable coating is to act as a carrier for the antimicrobial agents. Once placed, the polymer resorbs in approximately 140 days, leaving a lightweight permanent mesh incorporated into the tissue.
AIGISRx releases the antimicrobial agents rifampin and minocycline for a minimum of 7 days to reduce the risk of infection of the implanted pulse generator following surgery. In in-vitro studies, AIGISRx demonstrated antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus capitis, Acinetobacter baumanii, Enterobacter aerogenes, and Proteus mirabilis.